¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26
±³À°ÀÏÀÚ : 2019-05-26
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¹é¾ç´©¸® ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : 2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ 
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѸð¹ßÇÐȸ  
´ã´çÀÚ : ÇãâÈÆ
¿¬¶ôó : 031-787-7310  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í Á¤È¸¿ø, ¿¬±¸È¸¿ø(¿¬È¸ºñÆ÷ÇÔ): »çÀüµî·Ï 4¸¸¿ø, ÇöÀåµî·Ï 5¸¸¿øÀüȸ¿ø, ¿¬±¸È¸¿ø(ȸºñ³³ºÎȸ¿ø): »çÀüµî·Ï 2¸¸¿ø, ÇöÀåµî·Ï 3¸¸¿øºñȸ¿ø(ÇǺΰúÀü¹®ÀÇ, °¡ÀÔºñ Æ÷ÇÔ):»çÀüµî·Ï 7¸¸¿ø, ÇöÀåµî·Ï 8¸¸¿øÇǺΰú(Àü°øÀÇ,±ºÀÇ°ü,°øº¸ÀÇ), ¿¬±¸ÁØȸ¿ø: »çÀüµî·Ï 1¸¸¿ø, ÇöÀåµî·Ï 2¸¸¿øÇǺΰú ¿Ü Ÿ°ú ºñȸ¿ø: 50¸¸¿ø(ÇöÀåµî·Ï¸¸ °¡´É)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:00~09:15 Epidemiological Studies of Alopecia Areata Using National Health Insurance Service-National Sample Cohort (NHIS-NSC)  ÃÖÁö¿õ(¾ÆÁÖ´ë) 
±âŸ 05-26 ±×·£µåº¼·ë 09:15~09:30 °³È¸½Ä  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:30~09:45 Skin equivalent assay: an optimized method for testing for hair growth reconstitution capacity of epidermal and dermal cells.  ¹é½Âȯ(¾Æ»êÀÇ·á¿ø) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:45~10:00 Induction of alopecia areata in C3H/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma.  ÀÌ¿µ(Ãæ³²´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 10:00~10:30 Follicle mitochondria as a target for hair loss treatment  Thomas Dawson(A*Star) 
È޽Ġ05-26 ±×·£µåº¼·ë 10:30~10:45 Coffee Break  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 10:45~11:05 The kitchen garden roles of DPC cells in bench to clinic for hair disorders.  °­ÈÆ(Ä«Å縯´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:10~11:35 Revisiting the pathophysiology of hair loss disorders for better management - a physician-scientist  Manabu Ohyama(Kyorin University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:35~11:45 Quality of life in Korean alopecic patient: nationalwide studies supported by the Korean Hair Research Society  ÃÖ±¤¼º(ÀÎÇÏ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:45~11:55 Neuroendocrine system in hair growth  Koji Sugawara(Osaka City University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:55~12:05 Dermoscopy uses for hair & scalp diseases.  ±è¹®¹ü(ºÎ»ê´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 12:05~12:15 Folliculitis decalvans: Study of clinical and histopathological features  Masaki Uchiyama(Tokyo Medical University) 
½Ä»ç 05-26 ±×·£µåº¼·ë 12:15~13:20 Á¡½É½Ä»ç  () 
Åä·Ð 05-26 ±×·£µåº¼·ë 13:20~14:05 ÀÚÀ¯¿¬Á¦  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:05~14:35 Efficacy and safety of finasteride for ten years of over 300 AGA patients in Japan.  Akio Sato(Tokyo Memorial Clinic) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:35~14:50 The treatment of AGA with 5AR inhibitor in elderly and female patients  À¯¹Ú¸°(°æÈñ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:50~15:05 Tranomic analysis of balding and non-balding scalp in male pattern baldness and female pattern hair loss.  ¹Úº´Ã¶(´Ü±¹´ë) 
È޽Ġ05-26 ±×·£µåº¼·ë 15:05~15:20 Coffee Break  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 15:20~15:50 Review Update on Alopecia Areata  Kevin McElwee(Bradford University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 15:50~16:05 Mechanism: JAK inhibitor and mesenchymal stem cell therapy to treat alopecia areata  ±èÁ¤Àº(Ä«Å縯´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:05~16:20 Oral tofacitinib for moderate-to-severe alopecia areata from clinician's view point  ¹ÚÇö¼±(¼­¿ï´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:20~16:35 Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata.  ¹ÚÁø(ÀüºÏ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:35~16:50 Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study.  Á¶¼ººó(¿¬¼¼¼¼¶õÇǺΰú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÇѸ²´ëÇб³°­µ¿¼º½Éº´¿ø 2019³â 5¿ù ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2019-05-28
´ÙÀ½±Û 2019³âµµ ´ëÇÑÅëÁõÇÐȸ Ãá°è ¿¬¼ö±³À° : 2019-05-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 95 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 32 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 58 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 52 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 49 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 84 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 82 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 107 2024-05-10
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 66 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 52 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 82 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 31 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 91 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 76 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 14 2024-05-10
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷